Mechanisms of resistance to combined osimertinib and savolitinib in #EGFR-mutant #NSCLC (TATTON trial), presented by A. Markovets @AACR #AACR21.
ctDNA profiling revealed acquired -mainly compound- MET mutations. Genomic alterations in EGFR, KRAS and PIK3CA were also observed.
Nature Medicine Tcell, lungcancer, immunotherapy, NSCLC, TRACERx, AACR21: 11/04/2021 14:52:29
@CharlesSwanton @NickyMcGranahan A survey of #Tcell repertoire evolution in patients with early-stage untreated #lungcancer offers an opportunity to monitor and identify neoantigen-specific T cells for personalized #immunotherapy @BennyChain @QuezadaLab #NSCLC #TRACERx #AACR21
Elizabeth McKenna KRAS, G12C, AACR21: 11/04/2021 13:30:00
Early results showed #KRAS #G12C inhibitors were less active in CRC than NSCLC; a 2020 @CD_AACR paper by @Sandra_Misale @Albert0Bardelli et al suggested that the lower responses might be due to EGFR, a la what had been seen with BRAF inhibitors /4 #AACR21
Earlier diagnosis and biomarker testing should be more widely implemented to identify patients with EGFR-positive non–small lung cancer who may benefit for EGFR inhibition. #LCSM
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
Xiuning Le, MD, PhD, discusses the limited treatment options available for patients with non–small cell lung cancer and an EGFR exon 20 mutation. #LCSM
